An Observational Study On The Safety And Tolerability Of Prolonged Thrombosis Prophylaxis With Fragmin®

NCT01046903

Last updated date
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Venous Thromboembolism
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female patient, undergoing major orthopedic surgery

- At least 18 years old

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Hypersensitivity to Fragmin or other low molecular weight heparins or unfractioned
heparin;


- History of heparin induced thrombocytopaenia type II


- Acute gastroduodenal ulcer, cerebral haemorrhage, or other active haemorrhage.


- Serious coagulation disorder;


- Septic endocarditis;


- Injuries to and operations in the central nervous system, eye and ear within one month
before orthopaedic surgery;


- Spinal or epidural anesthesia or other procedures requiring spinal puncture and
concomitant treatment with high doses of dalteparin (such as those needed to treat
acute deep vein thrombosis, pulmonary embolism, and Unstable coronary artery disease);


- Patients with serum creatinine level > 150 umol/l;


- Platelet count of less than 100 000 per cubic millimeter at the beginning of the
therapy;


- High probability that patient will not return to the centre for follow-up;


- Patient on oral anticoagulation therapy in the last 7 days;


- Ongoing anticoagulant therapy with other medications or non-pharmacologic therapy
during the study period;


- Weight less than 40 kg;


- Simultaneous participation in another pharmacological study or receiving any
investigational drug 30 days or less before surgery;


- Pregnancy or breastfeeding;


- Clinically significant hepatic dysfunction.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Venous ThromboembolismDalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients NCT00445328
  1. Hyderabad, Andhra Pradesh
  2. Ahmedabad, Gujarat
  3. Trichur, Kerala
  4. Indore, Madhya Pradesh
  5. Chennai, Tamil Nadu
  6. Kolkata, West Bengal
  7. Kolkata, West Bengal
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Venous ThromboembolismAn Observational Study On The Safety And Tolerability Of Prolonged Thrombosis Prophylaxis With Fragmin® NCT01046903
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Venous ThromboembolismFragmin for the Treatment of Acute VTE in Pediatric Cancer Patients NCT00952380
  1. Aurora, Colorado
  2. Washington, District of Columbia
  3. Jacksonville, Florida
  4. Jacksonville, Florida
  5. Tampa, Florida
  6. Tampa, Florida
  7. Tampa, Florida
  8. Tampa, Florida
  9. Tampa, Florida
  10. Detroit, Michigan
  11. Kansas City, Missouri
  12. Memphis, Tennessee
  13. El Paso, Texas
  14. El Paso, Texas
  15. Houston, Texas
  16. Houston, Texas
  17. Houston, Texas
  18. Oslo,
  19. Oslo,
  20. Kazan, Republic Tatarstan
  21. Kazan, Republic Tatarstan
  22. Moscow,
  23. Ljubljana,
  24. Ljubljana,
  25. Boadilla del Monte, Madrid
  26. Boadilla del Monte, Madrid
ALL GENDERS
0+
years
MULTIPLE SITES
Venous ThromboembolismApixaban for the Acute Treatment of Venous Thromboembolism in Children NCT02464969
  1. New Brunswick, New Jersey
  2. New Brunswick, New Jersey
  3. Sioux Falls, South Dakota
  4. Sioux Falls, South Dakota
  5. Sioux Falls, South Dakota
  6. Sioux Falls, South Dakota
  7. Haifa,
  8. Birmingham, Alabama
  9. Birmingham, Alabama
  10. Birmingham, Alabama
  11. Phoenix, Arizona
  12. Loma Linda, California
  13. Loma Linda, California
  14. Loma Linda, California
  15. Madera, California
  16. Oakland, California
  17. Oakland, California
  18. Oakland, California
  19. Palo Alto, California
  20. Palo Alto, California
  21. Palo Alto, California
  22. Roseville, California
  23. Sacramento, California
  24. Sacramento, California
  25. San Bernardino, California
  26. San Francisco, California
  27. San Francisco, California
  28. San Francisco, California
  29. Aurora, Colorado
  30. Aurora, Colorado
  31. Hartford, Connecticut
  32. Wilmington, Delaware
  33. Washington, District of Columbia
  34. Hollywood, Florida
  35. Hollywood, Florida
  36. Orlando, Florida
  37. Orlando, Florida
  38. Orlando, Florida
  39. Orlando, Florida
  40. Tampa, Florida
  41. West Palm Beach, Florida
  42. West Palm Beach, Florida
  43. Atlanta, Georgia
  44. Atlanta, Georgia
  45. Atlanta, Georgia
  46. Peoria, Illinois
  47. Indianapolis, Indiana
  48. Indianapolis, Indiana
  49. Indianapolis, Indiana
  50. Iowa City, Iowa
  51. Lexington, Kentucky
  52. New Orleans, Louisiana
  53. Boston, Massachusetts
  54. Ann Arbor, Michigan
  55. Detroit, Michigan
  56. Detroit, Michigan
  57. Jackson, Mississippi
  58. Hackensack, New Jersey
  59. New Brunswick, New Jersey
  60. New York, New York
  61. New York, New York
  62. New York, New York
  63. New York, New York
  64. New York, New York
  65. New York, New York
  66. Syracuse, New York
  67. Durham, North Carolina
  68. Durham, North Carolina
  69. Akron, Ohio
  70. Cincinnati, Ohio
  71. Cleveland, Ohio
  72. Cleveland, Ohio
  73. Columbus, Ohio
  74. Dayton, Ohio
  75. Oklahoma City, Oklahoma
  76. Oklahoma City, Oklahoma
  77. Philadelphia, Pennsylvania
  78. Philadelphia, Pennsylvania
  79. Philadelphia, Pennsylvania
  80. Philadelphia, Pennsylvania
  81. Pittsburgh, Pennsylvania
  82. Charleston, South Carolina
  83. Charleston, South Carolina
  84. Nashville, Tennessee
  85. Nashville, Tennessee
  86. Nashville, Tennessee
  87. Houston, Texas
  88. Houston, Texas
  89. Houston, Texas
  90. San Antonio, Texas
  91. San Antonio, Texas
  92. Salt Lake City, Utah
  93. Seattle, Washington
  94. Milwaukee, Wisconsin
  95. West Allis, Wisconsin
  96. Randwick, New South Wales
  97. Sydney, New South Wales
  98. Innsbruck, Tyrol
  99. Innsbruck,
  100. Wien,
  101. Hamilton, Ontario
  102. Ottawa, Ontario
  103. Berlin,
  104. Duisburg,
  105. Leipzig,
  106. Munchen,
  107. Beer Sheva,
  108. Beer Sheva,
  109. Beer Sheva,
  110. Haifa,
  111. Ramat Gan,
  112. Coimbra,
  113. Lisboa,
  114. Kazan, Republic Tatarstan
  115. Yekaterinburg, Sverdlovsk Region
  116. Moscow,
  117. Moscow,
  118. Boadilla del Monte, Madrid
  119. Barcelona,
  120. Barcelona,
  121. Madrid,
  122. Dnipro,
  123. Kyiv,
  124. Kyiv,
  125. Zaporizhzhia,
  126. Glasgow, Scotland
  127. Newcastle upon Tyne, Tyne & Wear
  128. Cardiff, Wales
  129. Cardiff, Wales
  130. Birmingham, WEST Midlands
  131. Birmingham,
  132. Newcastle Upon Tyne,
ALL GENDERS
0+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title An Observational Study On The Safety And Tolerability Of Prolonged Thrombosis Prophylaxis With Fragmin®
Official Title An Observational Study On The Safety And Tolerability Of Prolonged Thrombosis Prophylaxis With Fragmin® (Dalteparin Sodium) In Patients Undergoing Major Orthopedic Surgery
Brief Summary The objective of this study is to observe the safety, tolerability, and compliance in the use of Fragmin® for prolonged thromboprophylaxis in post-surgery high-risk orthopedic patients.
Detailed Description All patients prescribed Fragmin® (Dalteparin Sodium) for prolonged thromboprophylaxis will be eligible for study
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population The adult population (women and men) after major orthopedic surgery.
Condition Venous Thromboembolism
Intervention Drug: Fragmin® (Dalteparin Sodium)
Administered per prescribing physician
Study Groups/Cohorts 1
Intervention: Drug: Fragmin® (Dalteparin Sodium)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: January 3, 2012)
503
Original Estimated Enrollment
 (submitted: January 11, 2010)
600
Actual Study Completion Date February 2011
Actual Primary Completion Date February 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Male or female patient, undergoing major orthopedic surgery
  • At least 18 years old

Exclusion Criteria:

  • Hypersensitivity to Fragmin or other low molecular weight heparins or unfractioned heparin;
  • History of heparin induced thrombocytopaenia type II
  • Acute gastroduodenal ulcer, cerebral haemorrhage, or other active haemorrhage.
  • Serious coagulation disorder;
  • Septic endocarditis;
  • Injuries to and operations in the central nervous system, eye and ear within one month before orthopaedic surgery;
  • Spinal or epidural anesthesia or other procedures requiring spinal puncture and concomitant treatment with high doses of dalteparin (such as those needed to treat acute deep vein thrombosis, pulmonary embolism, and Unstable coronary artery disease);
  • Patients with serum creatinine level > 150 umol/l;
  • Platelet count of less than 100 000 per cubic millimeter at the beginning of the therapy;
  • High probability that patient will not return to the centre for follow-up;
  • Patient on oral anticoagulation therapy in the last 7 days;
  • Ongoing anticoagulant therapy with other medications or non-pharmacologic therapy during the study period;
  • Weight less than 40 kg;
  • Simultaneous participation in another pharmacological study or receiving any investigational drug 30 days or less before surgery;
  • Pregnancy or breastfeeding;
  • Clinically significant hepatic dysfunction.
Sex/Gender
Sexes Eligible for Study:All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT01046903
Other Study ID Numbers A6301085
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date February 2012